| Literature DB >> 29545955 |
Abstract
Rescoring is a simple approach that theoretically could improve the original docking results. In this study AutoDock Vina was used as a docked engine and three other scoring functions besides the original scoring function, Vina, as well as their combinations as consensus scoring functions were employed to explore the effect of rescoring on virtual screenings that had been done on diverse targets. Rescoring by DrugScore produces the most number of cases with significant changes in screening power. Thus, the DrugScore results were used to build a simple model based on two binding site descriptors that could predict possible improvement by DrugScore rescoring. Furthermore, generally the screening power of all rescoring approach as well as original AutoDock Vina docking results correlated with the Maximum Theoretical Shape Complementarity (MTSC) and Maximum Distance from Center of Mass and all Alpha spheres (MDCMA). Therefore, it was suggested that, with a more complete set of binding site descriptors, it could be possible to find robust relationship between binding site descriptors and response to certain molecular docking programs and scoring functions. The results could be helpful for future researches aiming to do a virtual screening using AutoDock Vina and/or rescoring using DrugScore.Entities:
Year: 2018 PMID: 29545955 PMCID: PMC5818911 DOI: 10.1155/2018/3829307
Source DB: PubMed Journal: Int J Med Chem ISSN: 2090-2077
Data set characteristics.
| Abbreviation used in DUD-E | Target name | PDB code | Number of ligands | Number of decoys |
|---|---|---|---|---|
| ADA | Adenosine deaminase | 2E1W | 93 | 5444 |
| AKT2 | Serine/threonine-protein kinase AKT2 | 3D0E | 116 | 6891 |
| COMT | Catechol O-methyltransferase | 3BWM | 41 | 3846 |
| CP2C9 | Cytochrome P450 2C9 | 1R9O | 120 | 7435 |
| CXCR4 | C-X-C chemokine receptor type 4 | 3ODU | 40 | 3406 |
| DEF |
| 1LRU | 102 | 5686 |
| FA7 | Coagulation factor VII | 1W7X | 114 | 6239 |
| FKB1A | FK506-binding protein 1A | 1J4H | 111 | 5797 |
| GLCM | Beta-glucocerebrosidase | 2V3F | 54 | 3799 |
| GRIK1 | Glutamate receptor ionotropic kainate 1 | 1VSO | 101 | 6540 |
| HS90A | Heat shock protein HSP 90-alpha | 1UYG | 88 | 4848 |
| HXK4 | Hexokinase type IV (human pancreatic glucokinase in complex with glucose and activator) | 3F9M | 91 | 4692 |
| INHA | Enoyl-[acyl-carrier-protein] reductase ( | 2H7L | 43 | 2297 |
| KIF11 | Kinesin-like protein 1 | 3CJO | 116 | 6844 |
| KITH | Stem cell growth factor receptor (KIT kinase domain in complex with sunitinib) | 2B8T | 57 | 2850 |
| MAPK2 | MAP kinase-activated protein kinase 2 | 3M2W | 101 | 6144 |
| MCR | Mineralocorticoid receptor | 2AA2 | 90 | 4835 |
| MK01 | MAP kinase ERK2 | 2OJG | 79 | 4548 |
| MK10 | c-Jun N-terminal kinase 3 (mitogen-activated protein kinase 10) | 2ZDT | 104 | 6593 |
| NOS1 | Nitric-oxide synthase, brain | 1QW6 | 100 | 8037 |
| NRAM | Neuraminidase (influenza virus neuraminidase) | 1B9V | 98 | 6196 |
| PA2GA | Phospholipase A2 group IIA | 1KVO | 99 | 5143 |
| PLK1 | Serine/threonine-protein kinase PLK1 | 2OWB | 107 | 6794 |
| PUR2 | GAR transformylase | 1NJS | 50 | 2694 |
| PYGM | Muscle glycogen phosphorylase | 1C8K | 77 | 3940 |
| PYRD | Dihydroorotate dehydrogenase | 1D3G | 111 | 6443 |
| RENI | Renin | 3G6Z | 104 | 6954 |
| ROCK1 | Rho-associated protein kinase 1 | 2ETR | 100 | 6293 |
| SAHH | Adenosylhomocysteinase | 1LI4 | 62 | 3438 |
| THB | Thyroid hormone receptor beta-1 | 1Q4X | 103 | 7349 |
| TYSY | Thymidylate synthase | 1SYN | 109 | 6732 |
| WEE1 | Serine/threonine-protein kinase WEE1 | 3BIZ | 102 | 6135 |
| XIAP | Inhibitor of apoptosis protein 3 | 3HL5 | 100 | 5143 |
Average of AUC of the ROC curve and EF at different level obtained with each scoring approach (v: AutoDock Vina, c: ChemScore, d: DrugScore, and a: AutoDock 4.2).
| Scoring | AUC | EF20% | EF10% | EF2% | EF1% | EF0.2% | EF0.1% |
|---|---|---|---|---|---|---|---|
|
| 0.671 | 2.137 | 2.93 | 6.394 | 8.576 | 11.17 | 12.74 |
|
| 0.61 | 1.855 | 2.33 | 3.567 | 4.007 | 4.513 | 3.54 |
|
| 0.65 | 1.942 | 2.72 | 5.253 | 6.275 | 8.766 | 9.242 |
|
| 0.623 | 1.831 | 2.5 | 4.441 | 4.949 | 7.301 | 8.866 |
|
| 0.668 | 2.162 | 3.08 | 6.714 | 8.173 | 8.753 | 10.01 |
|
| 0.667 | 2.174 | 3.01 | 6.537 | 8.768 | 9.746 | 9.515 |
|
| 0.677 | 2.2 | 3.21 | 7.096 | 9.169 | 11.72 | 14 |
|
| 0.661 | 2.088 | 3.01 | 5.989 | 7.25 | 8.371 | 7.76 |
|
| 0.652 | 2.068 | 2.84 | 5.158 | 6.086 | 7.41 | 7.47 |
|
| 0.656 | 2.087 | 2.93 | 6.233 | 7.28 | 7.564 | 7.415 |
|
| 0.679 | 2.14 | 3.08 | 7.026 | 9.292 | 13.21 | 14.76 |
|
| 0.671 | 2.192 | 3.05 | 6.074 | 8.562 | 11.72 | 15.66 |
|
| 0.646 | 2.012 | 2.77 | 4.916 | 5.986 | 6.896 | 6.06 |
|
| 0.631 | 1.895 | 2.53 | 4.322 | 5.057 | 7.324 | 6.865 |
|
| 0.658 | 2.026 | 2.85 | 5.579 | 7.182 | 8.688 | 8.51 |
Average of difference between each rescoring approach in terms of AUC of the ROC curve and EF and original AutoDock Vina scoring (v: AutoDock Vina, c: ChemScore, d: DrugScore, and a: AutoDock 4.2).
| Scoring | AUC | EF20% | EF10% | EF2% | EF1% | EF0.2% | EF0.1% |
|---|---|---|---|---|---|---|---|
|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
|
| −0.061 | −0.282 | −0.600 | −2.827 | −4.569 | −6.662 | −9.201 |
|
| −0.021 | −0.195 | −0.211 | −1.140 | −2.301 | −2.409 | −3.499 |
|
| −0.048 | −0.306 | −0.432 | −1.953 | −3.627 | −3.874 | −3.875 |
|
| −0.003 | 0.026 | 0.144 | 0.321 | −0.403 | −2.421 | −2.736 |
|
| −0.004 | 0.037 | 0.074 | 0.143 | 0.192 | −1.429 | −3.226 |
|
| 0.006 | 0.063 | 0.281 | 0.702 | 0.593 | 0.541 | 1.263 |
|
| −0.010 | −0.049 | 0.072 | −0.405 | −1.325 | −2.804 | −4.982 |
|
| −0.019 | −0.068 | −0.091 | −1.236 | −2.490 | −3.765 | −5.271 |
|
| −0.015 | −0.050 | −0.003 | −0.161 | −1.296 | −3.611 | −5.326 |
|
| 0.008 | 0.004 | 0.147 | 0.632 | 0.716 | 2.033 | 2.014 |
|
| 0.000 | 0.055 | 0.119 | −0.320 | −0.014 | 0.543 | 2.920 |
|
| −0.025 | −0.124 | −0.167 | −1.478 | −2.590 | −4.279 | −6.681 |
|
| −0.040 | −0.242 | −0.399 | −2.072 | −3.519 | −3.850 | −5.877 |
|
| −0.013 | −0.111 | −0.084 | −0.814 | −1.394 | −2.487 | −4.231 |
AUC of the ROC curve obtained with each scoring method for individual targets (v: AutoDock Vina, c: ChemScore, d: DrugScore, and a: AutoDock 4.2; sorted based on AutoDock Vina performance).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WEE1 | 0.949 | 0.828 | 0.841 | 0.555 | 0.917 | 0.909 | 0.927 | 0.915 | 0.853 | 0.916 | 0.930 | 0.910 | 0.852 | 0.776 | 0.800 |
| FA7 | 0.917 | 0.890 | 0.876 | 0.878 | 0.929 | 0.936 | 0.926 | 0.927 | 0.909 | 0.935 | 0.929 | 0.920 | 0.908 | 0.897 | 0.898 |
| MAPK2 | 0.886 | 0.775 | 0.776 | 0.717 | 0.877 | 0.850 | 0.877 | 0.888 | 0.848 | 0.861 | 0.849 | 0.891 | 0.809 | 0.826 | 0.823 |
| KIF11 | 0.858 | 0.845 | 0.806 | 0.840 | 0.860 | 0.860 | 0.856 | 0.865 | 0.846 | 0.867 | 0.852 | 0.864 | 0.842 | 0.849 | 0.835 |
| TYSY | 0.847 | 0.607 | 0.698 | 0.770 | 0.781 | 0.768 | 0.820 | 0.778 | 0.726 | 0.760 | 0.822 | 0.829 | 0.675 | 0.710 | 0.762 |
| PYRD | 0.826 | 0.749 | 0.768 | 0.730 | 0.791 | 0.807 | 0.795 | 0.784 | 0.767 | 0.803 | 0.817 | 0.789 | 0.778 | 0.747 | 0.763 |
| PUR2 | 0.819 | 0.393 | 0.856 | 0.691 | 0.749 | 0.762 | 0.827 | 0.667 | 0.702 | 0.641 | 0.869 | 0.777 | 0.696 | 0.557 | 0.801 |
| MK01 | 0.806 | 0.767 | 0.632 | 0.629 | 0.748 | 0.777 | 0.719 | 0.774 | 0.702 | 0.816 | 0.747 | 0.748 | 0.726 | 0.721 | 0.639 |
| AKT2 | 0.778 | 0.744 | 0.699 | 0.803 | 0.801 | 0.788 | 0.810 | 0.794 | 0.795 | 0.776 | 0.786 | 0.806 | 0.765 | 0.785 | 0.799 |
| THB | 0.777 | 0.484 | 0.490 | 0.578 | 0.632 | 0.630 | 0.665 | 0.700 | 0.504 | 0.693 | 0.670 | 0.777 | 0.480 | 0.523 | 0.510 |
| MK10 | 0.746 | 0.701 | 0.653 | 0.598 | 0.694 | 0.721 | 0.682 | 0.697 | 0.666 | 0.737 | 0.716 | 0.684 | 0.692 | 0.659 | 0.633 |
| FKB1A | 0.693 | 0.755 | 0.657 | 0.668 | 0.730 | 0.745 | 0.697 | 0.734 | 0.724 | 0.755 | 0.702 | 0.690 | 0.738 | 0.736 | 0.676 |
| INHA | 0.688 | 0.680 | 0.715 | 0.693 | 0.719 | 0.722 | 0.719 | 0.708 | 0.712 | 0.705 | 0.723 | 0.702 | 0.712 | 0.696 | 0.714 |
| KITH | 0.688 | 0.532 | 0.699 | 0.621 | 0.646 | 0.655 | 0.667 | 0.628 | 0.632 | 0.631 | 0.692 | 0.654 | 0.636 | 0.592 | 0.658 |
| SAHH | 0.677 | 0.290 | 0.708 | 0.615 | 0.590 | 0.575 | 0.719 | 0.516 | 0.539 | 0.478 | 0.726 | 0.685 | 0.512 | 0.391 | 0.694 |
| ROCK1 | 0.666 | 0.660 | 0.594 | 0.654 | 0.668 | 0.662 | 0.659 | 0.678 | 0.657 | 0.680 | 0.642 | 0.674 | 0.645 | 0.666 | 0.641 |
| CXCR4 | 0.661 | 0.726 | 0.604 | 0.723 | 0.706 | 0.687 | 0.685 | 0.729 | 0.706 | 0.718 | 0.640 | 0.712 | 0.682 | 0.735 | 0.681 |
| XIAP | 0.632 | 0.676 | 0.789 | 0.678 | 0.724 | 0.739 | 0.722 | 0.681 | 0.741 | 0.669 | 0.741 | 0.668 | 0.772 | 0.694 | 0.742 |
| RENI | 0.620 | 0.686 | 0.781 | 0.588 | 0.694 | 0.733 | 0.688 | 0.638 | 0.707 | 0.664 | 0.742 | 0.605 | 0.759 | 0.642 | 0.703 |
| PLK1 | 0.619 | 0.628 | 0.668 | 0.548 | 0.628 | 0.653 | 0.625 | 0.605 | 0.625 | 0.629 | 0.659 | 0.588 | 0.659 | 0.592 | 0.620 |
| CP2C9 | 0.613 | 0.604 | 0.552 | 0.563 | 0.597 | 0.607 | 0.588 | 0.605 | 0.582 | 0.622 | 0.593 | 0.597 | 0.588 | 0.587 | 0.564 |
| PA2GA | 0.607 | 0.795 | 0.692 | 0.814 | 0.791 | 0.760 | 0.768 | 0.783 | 0.812 | 0.746 | 0.696 | 0.744 | 0.771 | 0.821 | 0.801 |
| PYGM | 0.594 | 0.597 | 0.561 | 0.446 | 0.561 | 0.597 | 0.543 | 0.555 | 0.540 | 0.608 | 0.583 | 0.530 | 0.588 | 0.522 | 0.502 |
| NOS1 | 0.570 | 0.551 | 0.506 | 0.492 | 0.545 | 0.545 | 0.533 | 0.570 | 0.533 | 0.570 | 0.533 | 0.569 | 0.533 | 0.551 | 0.506 |
| DEF | 0.541 | 0.262 | 0.632 | 0.578 | 0.502 | 0.465 | 0.602 | 0.456 | 0.485 | 0.384 | 0.602 | 0.569 | 0.427 | 0.415 | 0.621 |
| GRIK1 | 0.538 | 0.464 | 0.492 | 0.442 | 0.483 | 0.500 | 0.493 | 0.480 | 0.460 | 0.503 | 0.518 | 0.495 | 0.480 | 0.439 | 0.467 |
| NRAM | 0.526 | 0.522 | 0.608 | 0.443 | 0.537 | 0.574 | 0.537 | 0.496 | 0.537 | 0.530 | 0.581 | 0.478 | 0.589 | 0.481 | 0.536 |
| COMT | 0.525 | 0.371 | 0.363 | 0.736 | 0.575 | 0.398 | 0.645 | 0.646 | 0.593 | 0.431 | 0.439 | 0.750 | 0.340 | 0.688 | 0.690 |
| ADA | 0.520 | 0.377 | 0.500 | 0.435 | 0.438 | 0.444 | 0.479 | 0.428 | 0.417 | 0.430 | 0.509 | 0.474 | 0.416 | 0.395 | 0.459 |
| HX4 | 0.515 | 0.552 | 0.590 | 0.534 | 0.550 | 0.554 | 0.549 | 0.533 | 0.563 | 0.532 | 0.555 | 0.524 | 0.573 | 0.545 | 0.566 |
| MCR | 0.498 | 0.656 | 0.639 | 0.563 | 0.628 | 0.634 | 0.571 | 0.589 | 0.691 | 0.584 | 0.571 | 0.495 | 0.699 | 0.665 | 0.634 |
| GLCM | 0.486 | 0.471 | 0.548 | 0.541 | 0.520 | 0.506 | 0.536 | 0.506 | 0.528 | 0.484 | 0.517 | 0.520 | 0.515 | 0.507 | 0.559 |
| HS90A | 0.250 | 0.321 | 0.393 | 0.369 | 0.308 | 0.290 | 0.295 | 0.316 | 0.346 | 0.270 | 0.296 | 0.294 | 0.338 | 0.310 | 0.378 |
Pearson correlation coefficients between each rescoring approach and binding site descriptors (v: AutoDock Vina, c: ChemScore, d: DrugScore, and a: AutoDock 4.2).
| Pocket volume | Number of alpha spheres | Mean alpha sphere radius | Proportion of apolar alpha spheres | Mean local hydrophobic density | Hydrophobicity score | Volume score | Charge score | Proportion of polar atoms | Alpha sphere density | Max Dist. from Center of Mass and all Alpha spheres | Maximum Theoretical Shape Complementarity | Observed shape complementarity | Normalized shape complementarity | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 0.415 | 0.418 | −0.055 | 0.001 | 0.249 | −0.108 | −0.190 | 0.170 | 0.098 | 0.458 | 0.594 | 0.532 | 0.439 | 0.085 |
|
| 0.509 | 0.400 | 0.068 | 0.126 | 0.266 | 0.131 | −0.153 | 0.320 | −0.204 | 0.445 | 0.459 | 0.462 | 0.304 | −0.042 |
|
| 0.510 | 0.387 | 0.111 | −0.066 | 0.161 | −0.011 | 0.014 | 0.171 | 0.141 | 0.366 | 0.555 | 0.719 | 0.474 | −0.022 |
|
| 0.234 | 0.355 | 0.034 | 0.095 | 0.217 | 0.103 | 0.135 | 0.268 | −0.118 | 0.207 | 0.378 | 0.413 | 0.303 | 0.030 |
|
| 0.483 | 0.424 | 0.061 | 0.058 | 0.274 | 0.001 | −0.057 | 0.307 | −0.041 | 0.419 | 0.586 | 0.607 | 0.415 | −0.005 |
|
| 0.541 | 0.471 | 0.064 | 0.031 | 0.276 | 0.017 | −0.142 | 0.274 | −0.011 | 0.483 | 0.620 | 0.665 | 0.464 | 0.000 |
|
| 0.417 | 0.387 | 0.043 | 0.010 | 0.234 | −0.081 | −0.011 | 0.243 | 0.051 | 0.363 | 0.573 | 0.588 | 0.425 | 0.035 |
|
| 0.443 | 0.410 | 0.028 | 0.104 | 0.295 | 0.011 | −0.083 | 0.328 | −0.105 | 0.425 | 0.557 | 0.515 | 0.365 | 0.005 |
|
| 0.476 | 0.378 | 0.085 | 0.080 | 0.244 | 0.068 | 0.028 | 0.334 | −0.095 | 0.361 | 0.519 | 0.582 | 0.356 | −0.056 |
|
| 0.515 | 0.468 | 0.031 | 0.073 | 0.302 | 0.022 | −0.202 | 0.292 | −0.073 | 0.507 | 0.596 | 0.562 | 0.413 | 0.015 |
|
| 0.495 | 0.454 | 0.031 | −0.025 | 0.241 | −0.074 | −0.112 | 0.187 | 0.112 | 0.453 | 0.631 | 0.684 | 0.506 | 0.045 |
|
| 0.331 | 0.354 | −0.012 | 0.043 | 0.241 | −0.089 | −0.036 | 0.247 | 0.011 | 0.349 | 0.532 | 0.459 | 0.365 | 0.064 |
|
| 0.554 | 0.426 | 0.100 | 0.033 | 0.234 | 0.087 | −0.086 | 0.292 | −0.048 | 0.439 | 0.553 | 0.651 | 0.409 | −0.058 |
|
| 0.412 | 0.339 | 0.061 | 0.148 | 0.250 | 0.116 | 0.022 | 0.346 | −0.212 | 0.337 | 0.436 | 0.439 | 0.272 | −0.047 |
|
| 0.379 | 0.336 | 0.075 | 0.023 | 0.184 | −0.002 | 0.143 | 0.269 | 0.009 | 0.260 | 0.479 | 0.567 | 0.366 | −0.017 |
Figure 1Significant correlation between performance of DrugScore and MTSC descriptor (correlation coefficient = 0.719, p value < 0.001).
Difference between calculated AUC of the ROC curve after rescoring with DrugScore and original AUC of the ROC curve for each target (statistically significant changes).
| Receptor |
|
|---|---|
| THB | −0.2876 |
| MK01 | −0.1738 |
| COMT | −0.1625 |
| TYSY | −0.1491 |
| WEE1 | −0.1083 |
| MK10 | −0.0929 |
| AKT2 | −0.0787 |
| ROCK1 | −0.0715 |
| NOS1 | −0.0641 |
| CP2C9 | −0.0605 |
| PYRD | −0.0582 |
| CXCR4 | −0.0569 |
| KIF11 | −0.0518 |
| GRIK1 | −0.0467 |
| FA7 | −0.0403 |
| FKB1A | −0.036 |
| PYGM | −0.0327 |
| ADA | −0.02 |
| KITH | 0.0107 |
| INHA | 0.0262 |
| SAHH | 0.0303 |
| PUR2 | 0.0364 |
| PLK1 | 0.0492 |
| GLCM | 0.062 |
| HX4 | 0.0753 |
| NRAM | 0.0812 |
| PA2GA | 0.0854 |
| DEF | 0.0906 |
| MCR | 0.1411 |
| HS90A | 0.1439 |
| XIAP | 0.1577 |
| RENI | 0.1605 |
Figure 2The cases with significant improvement in AUC of the ROC curves after rescoring with DrugScore (before: blue line; after: red dots).
Figure 3Separation of good and bad responders to DrugScore rescoring based on volume score and MTSC descriptors.